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Abstract
Objectives: The objective of this study was to determine whether alterations in the expression of p53, caspase-3 
Bcl-2, and ki-67 appear early in premalignant oral epithelium and show clonal behavior. 
Study Design: Samples from 41 tumors with their adjacent non-tumor epithelia were immunohistochemically 
analyzed using monoclonal antibodies that recognize p53, caspase-3, Bcl-2, and Ki-67 
Results: A statistically significant association was found between the expression in tumor and adjacent epithe-
lium of p53, caspase-3, and Bcl-2 but not of k-67. A significant association was observed between the expression 
of ki-67 and p53 in both localizations. In non-tumor (premalignant) epithelium samples, there was a significant 
inverse relationship between the expressions of p53 and caspase-3 and a significant direct relationship between 
the expressions of p53 and Bcl-2. 
Conclusions: Alterations in these proteins appear to operate in combination with premalignant epithelia to create 
hyperproliferative cell states that favor the acquisition of summative oncogenic errors that confer invasive capacity.
Key words: Cell cycle, apoptosis, p53, caspase-3, Bcl-2, Ki-67.
Bascones-Martínez A, Rodríguez-Gutierrez C, Rodríguez-Gómez E, 
Gil-Montoya JA, Gómez-Font R, González-Moles MA. Evaluation of p53, 
Caspase-3, Bcl-2, and Ki-67 markers in oral squamous cell carcinoma and 
premalignant epithelium in a sample from Alava Province (Spain). Med Oral 
Patol Oral Cir Bucal. 2013 Nov 1;18 (6):e846-50. 
http://www.medicinaoral.com/medoralfree01/v18i6/medoralv18i6p846.pdf
Article Number: 18901          http://www.medicinaoral.com/
© Medicina Oral S. L. C.I.F. B 96689336 - pISSN 1698-4447 - eISSN: 1698-6946
eMail:  medicina@medicinaoral.com 
Indexed in: 
Science Citation Index Expanded
Journal Citation Reports
Index Medicus, MEDLINE, PubMed
Scopus, Embase and Emcare 
Indice Médico Español
doi:10.4317/medoral.18901
http://dx.doi.org/doi:10.4317/medoral.18901
Med Oral Patol Oral Cir Bucal. 2013 Nov 1;18 (6):e846-50.                                                                                                                                          Tumor markers in a sample from a Spanish city
e847
Introduction
Cancerous cells are able to elude growth-inhibiting 
signals and develop mechanisms to evade apoptosis 
(1). They enter a pathological proliferative process that 
does not respond to exogenous growth signals, losing 
the main cell proliferation control mechanisms linked 
to the expression of tumor suppressor genes, whose 
main function is to halt the cell cycle for DNA repair, 
and developing anti-apoptotic molecular mechanisms 
(2). These molecular alterations are essential for can-
cer development and for the persistence of an uncon-
trolled proliferative state, in which the probability of 
oncogenic errors related to cell division increases due 
to so-called genomic instability. It is currently accepted 
that the development of oral cavity cancer is attribut-
able to summative oncogenic alterations that appear 
very early and result in a progression from epithelial 
dysplasia through in situ carcinoma to invasive disease 
(3,4). In this multistep process, precancerous epithelium 
may undergo malignant transformation through the al-
teration of chromosomal loci that host highly important 
tumor suppressor genes, such as 17p (5-7). Furthermore, 
molecular changes contributing to tumor development 
may be clonally transmitted by cells to their descend-
ants, generating cell hierarchies predisposed to acquire 
new disorders that would eventually be responsible for 
persistent tumor growth. 
Increasing knowledge of the molecular mechanisms in-
volved in cancer development has enabled the develop-
ment of molecular treatment strategies to reestablish the 
normal function of tumor suppressor genes in the tumor 
or to interrupt the intracellular pathways that transcribe 
aberrant growth signals, among other goals (1). Given 
that some disorders are established early, the application 
of these treatment strategies in premalignant cancer stag-
es would help to prevent progression to invasion. This 
approach requires precise knowledge of early molecular 
events in the development of oral cancer (8).
Non-tumor epithelium adjacent to oral cancer represents 
a good example of a premalignant field in which antitu-
mor control mechanisms have failed (9,10). In the present 
study, tumor and adjacent non-tumor epithelium (ANTE) 
samples were immunohistochemically analyzed,  evalu-
ating the expression of the following markers: ki-67, to 
determine the global fraction of proliferative cells as in-
direct evidence of self-sufficient tumor cell growth; p53, 
the main tumor suppressor protein; caspase 3, apoptotic 
marker; and Bcl-2, anti-apoptotic marker. The main ob-
jective of this study was to determine whether these pro-
teins are altered early in premalignant fields and whether 
they behave clonally in cancer development.
Material and Methods
The study included 41 patients with Oral Squamous 
Cell Carcinoma (OSCC) under treatment in the Hos-
pital of Txagorritxu (Osakidetza-Vitoria-Spain). After 
approval of the study by the hospital ethics committee, 
the hospital records of patients were reviewed and data 
were gathered on age, sex, reason for the first hospi-
tal visit, and the clinicopathological characteristics of 
the lesions, including their localization, size, stage, and 
degree of differentiation. Clinicopathological variables 
were considered missing when not found in the clinical 
records. Formalin-fixed and paraffin-embedded tumor 
tissue was available for all patients. The presence of 
ANTE with the tumors was recorded.
All biopsies were incisional and performed before the 
treatment, which was tumor resection in all cases. Only 
four patients (15% of the sample) were treated with ra-
diotherapy, and no patient received chemotherapy. Ac-
cording to the TNM staging system, 20 patients (50%) 
were T1N0M0, 17 patients (43%) T2N0M0, and 4 pa-
tients (7%) T3N0M0.
-Immunohistochemistry: For the immunohistochemi-
cal staining, 4-μm sections were cut from paraffin 
blocks. Peroxidase–antiperoxidase and avidin–biotin 
techniques were applied. The study was performed au-
tomatically using Autostainer Link equipment (Dako, 
Carpintería, CA, USA) and EmVision™FLEX reagents 
(K8002; Dako, Carpintería, CA, USA). Primary anti-
bodies were DO-7, Mib-1, anti-Bcl-2 (Dako, Carpin-
tería, CA, USA) and anti-caspase-3 (Pharmagen, San 
Diego, CA). Manufacturers’ instructions were rigor-
ously followed. For the negative control, the primary 
antibody was replaced with phosphate buffer saline. 
For the positive control, tissue was used from an OSCC 
sample known to intensively express each protein. The 
result was considered positive when a brown color ap-
peared in the cell nucleus (p53 and ki-67) or cytoplasm 
(caspase-3 and Bcl.2). Expression in premalignant and 
malignant epithelium was assessed in four randomized 
high-power fields (40×). Total cell number and number 
of positive cells were counted in each field, obtaining 
a mean percentage expression in each case. The count 
was made from the image on the computer screen.
Samples were assigned to one of the following categories, 
according to the mean percentage expression of positive 
cells found in each case: 0% positive cells (−), 1–25% 
positive cells (+), 26–50% positive cells (++), 51–75% 
positive cells (+++), or >75% positive cells (++++).  This 
categorization was applied for all antibodies. In order to 
simplify the immunohistochemistry study, the results 
were grouped in two categories (0-25% and 26-100%).
Histological and immunohistochemical analyses were 
always performed by the same experienced examiner 
(MAGM), who was blind to the clinical stage, treatment, 
and course of the disease. Furthermore, both intra- (MAGM 
vs MAGM, 1 week apart) and inter-examiner (MAGM vs 
JGM, another experienced examiner) concordances were 
tested by repeating the marker observations in 13 samples. 
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Quadratic weighted kappa values for intra- and inter-ex-
aminer concordance ranged from 0.62 to 0.95, considered 
adequate according to the Landis & Koch scale (11).
-Statistical analysis
SPSS 1.9 for Windows (IBM, Chicago IL) was used for 
the data analyses. A descriptive statistical analysis was 
performed (FREQUENCIES procedure), expressing 
qualitative data as frequencies and rates. Contingency 
tables were constructed (CROSSTABS procedure) to 
determine relationships among qualitative variables. 
The chi-square test and Pearson chi-square test were 
used to analyze independent qualitative variables. 
Results
Table 1 shows the results of comparing expressions of 
p53, caspase 3, Bcl-2 and Ki 67 between tumor tissue 
and the accompanying ANTE. For all markers, with 
the exception of ki-67, a higher expression in ANTE 
was accompanied by a higher expression in tumor tis-
sue. Table 2 compares the expression of p53 with the 
expressions of caspase-3, Bcl-2, and Ki-67 in the tu-
mor. A higher expression of ki-67 was accompanied 
by a higher expression of p53. Table 3 compares the 
expression of p53 with those of caspase-3, Bcl-2, and 
Ki-67 in the ANTE (Fig. 1). 
Discussion
This study analyzed the expression of cell cycle regula-
tors and proliferative markers in oral cancer. Limitations 
of this type of immunohistochemical study relate to the 
diverse antibodies used by different authors, the lack of 
agreement among researchers on cutoff points for con-
sidering a case positive, and difficulties in the evalua-
tion. Nevertheless, immunohistochemical analysis yields 
considerable data on the topographical expression of 
markers and the relationships of positive cells with the 
surrounding cells. Our  findings indicate that alterations 
in the expression and function of the main cell cycle-reg-
ulating proteins operate in combination with the multi-
step process of oral carcinogenesis to create a state of cell 
hyperproliferation (12), thereby favoring the occurrence 
of summative oncogenic events that enhance the prolif-
erative and invasive activity of tumor cell clones. In this 
study, p53 expressions in OSCCs and in their associated 
ANTE were significantly associated (Table 1), demon-
strating that p53 alterations are clonal and early onco-
genic events in the multistep carcinogenesis of the oral 
mucosa. Alterations of p53 constitute an essential com-
ponent of the oncogenic alterations that create genomic 
instability and decisively contribute to the transformation 
process rather than being secondary to the genomic in-
stability of cell clones in the malignancy pathway (13,14). 
Although immunohistochemistry has been reported to 
be an imprecise method to assess the mutational status 
of the p53 gene, due to discrepancies between protein ex-
pression and sequencing results, it is acknowledged that 
the immunohistochemical overexpression of p53 in pre-
malignant epithelium indicates an incorrect functioning 
of the p53-related control system (5). 
This interpretation is supported by our comparison be-
tween the expression of p53 and that of the other mark-
ers (Table 1). Thus, we observed a significant associa-
   p53 in ANTE
No ANTE
n(%)
Negative
n(%)
Positive
n(%)
p
p53 in tumor  
  0-25%
  26-100%
2 (22.2)
7 (77.7)
14 (63.6)
8 (36.3)
1 (11.1)
8 (88.8)
**
Caspase 3 in ANTE
Caspase 3 in tumor
  0-25%
  26-100%
7 (77.7)
2 (22.2)
15 (88.2)
2 (11.7)
0
2 (100.0)
**
Bcl-2 in ANTE
Bcl-2 in tumor
  0-25%
  26-100%
5 (55.5)
4 (44.4)
26 (92.8)
2 (7.14)
0
4 (100.0)
**
Ki 67 in ANTE
Ki 67 in tumor
  0-25%
  26-100%
2 (22.2)
7 (77.7)
3 (75.0)
1 (25.0)
6 (40.0)
9 (60.0)
NS
Table 1. Comparison of expressions of p53, Caspase 3, and Bcl-2and Ki-67 between tumor 
epithelium and adjacent non-tumor epithelium (ANTE).
** p<0.05; 
NS: not significant
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                                             p53 in tumor
0-25% 26-100% p
Caspase 3 in 
tumor
  0-25%
  26-100%
11 (84.6)
2 (15.3)
10 (66.6)
5 (83.3)
NS
Bcl2 in tumor
  0-25%
  26-100%
11 (84.6)
2 (15.3)
10 (62.5)
6 (37.5)
NS
Ki 67 in tumor
  0-25%
  26-100%
9 (75.0)
3 (25.0)
2 (12.5)
14 (87.5)
**
Table 2. Association between expression of p53 and expressions of 
Caspase 3, Bcl-2, and Ki 67 in tumor samples.
** p<0.05; 
      NS: not significant
                                               p53 in ANTE
Negative
n(%)
Positive
n(%)
p
Caspase 3 in ANTE
  Negative
  Positive
11 (78.5)
2 (14.2)
5 (100.0)
0 *
Bcl-2 in ANTE
  Negative
  Positive
19 (70.3)
8 (29.6)
3 (75.0)
1 (25.0)
*
Ki 67 in ANTE
  Negative
  Positive
5 (100.0)
0
9 (64.2)
4 (28.5)
*
Table 3. Association between expression of p53 and expressions of 
Caspase 3, Bcl-2, and Ki 67 in ANTE samples.
* p  <  0.05
Fig. 1. A) P53 nuclear expression in premalignant and malignant oral 
epithelia (x100; immunohistochemical technique). B) Cytoplasmatic 
expression of caspase-3 in oral carcinoma (x100; immunohistochem-
ical technique). C) Cytoplasmatic expression of Bcl-2 at the invasion 
front of the oral carcinoma (x100; immunohistochemical technique). 
D) High expression of ki-67 in an oral carcinoma (x100; immunohis-
tochemical technique).
tion between p53 and ki-67 in both tumor and ANTE, 
which may indicate that the overexpression of p53 cor-
responds to the loss of its cell-cycle repression func-
tions (Tables 2,3). Moreover, our finding of an inverse 
association between the expression of p53 and that of 
caspase-3 suggests that p53 is unable to arrest the cell 
cycle and also loses its apoptosis-inducing function in 
these epithelia (Tables 2,3). According to our results, the 
lack of apoptotic response in the ANTE is not only at-
tributable to the loss of p53 function but also to a direct 
anti-apoptotic mechanism linked to the overexpression 
of Bcl-2 (15). The two oncogenic mechanisms (loss of 
p53 function and Bcl-2 overexpression) appear to oper-
ate in combination to suppress the apoptotic response 
in premalignant epithelium (16). Evidently, apoptosis 
suppression does not globally affect all of the cells of 
premalignant epithelia. 
We observed caspase-3 expression in some areas of 
ANTE, and there was a significant association between 
the expression of caspase-3 in ANTE and tumor (Table 
3). In our opinion, this result indicates the presence of 
heterogeneous cell populations in premalignant fields 
and in the tumors that arise from them. Proliferation 
studies have shown that the persistent growth of a tumor 
or premalignant epithelium depends on a hierarchy of 
cells that have obtained a growth advantage, regardless 
of whether other cells in the same tissue develop apop-
tosis (9,10). Cells within the tumor that are capable of 
developing apoptosis would not contribute to persistent 
tumor growth. 
Finally, the lack of association between the expression of 
ki-67 in ANTE and in the associated tumor (Tables 2,3) 
indicates that the proliferative state in premalignant and 
malignant tissues varies according to the time course of 
the process and reflects the occurrence of late oncogen-
ic events in the malignant cell population. These events 
would derive from genomic instability secondary to 
p53 changes, which would endow specific cell clones 
with proliferative and invasive advantages (17). These 
alterations would result from a loss of p53 function after 
gene mutation or from its inactivation by other causes 
and also from the effects of the demonstrated oncogenic 
functions of mutated p53 protein (2).
Conclusions
Our results suggest that p53 alterations are decisive on-
cogenic events in multistep oral carcinogenesis, along-
side other oncogenic molecular processes that prevent 
the apoptotic response and lead to malignant transfor-
mation. Immunohistochemistry is a simple procedure 
that can be routinely applied and may help to identify 
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patients requiring special follow-up and therapeutic 
measures.  However, a wider study is required to verify 
these conclusions.
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